semaglutide sq Injectable – 4 mg/mL 1 receptor agonist). Standard Dose vs Microdose GLP-1:

(2024) Semaglutide vs Tirzepatide for Weight Loss, JAMA Internal Medicine FDA Prescribing Information: Wegovy (Semaglutide), 2025 Medical disclaimer This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment

However, some compounded formulations include additional ingredients like glycine or methylcobalamin that may modestly improve GI tolerance

Vomiting was reported by 24% of the patients, diarrhea by 30%, constipation 24%, abdominal pain 20%, headache 14%, fatigue (tiredness) 11%, indigestion 9%, dizziness 8%, abdominal bloating 7%, flatulence 6%, loud burping 7%, low blood sugar (hypoglycemia) 6% and other side effects

Semaglutide enhances glucose-dependent insulin secretion, meaning it only stimulates insulin release when blood sugar is elevated

He is an amazing person besides doctor